biosimulation

<!-- Name:DistributionId Value:8825357 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:2790 -->…

Pune, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The global biosimulation technology market is expected to clock US$ 9.44 billion by 2030 owing to increased investments in research and development by pharmaceutical and biotechnology firms,…

Pune, June 22, 2022 (GLOBE NEWSWIRE) -- The Global Biosimulation Market is expected to clock US$ ~10.3 billion by 2031 owing to the increasing demand for biosimulation for drug discovery and drug development applications and rising…

PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to…

PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug…

New York, US, July 07, 2021 (GLOBE NEWSWIRE) -- Biosimulation Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Biosimulation Market Information by Product, Application, Delivery Model,…

PRINCETON, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ and Phoenix™…